To value the late genitourinary (GU) morbidity in men treated with a hypofractionated radiotherapy regimen for prostate cancer. Patients with intermediate risk factors according to D'Amico's criteria were selected. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy. Significant changes in storage-symptoms were not found. A significant transient worsening in the score of late effects of normal tissue late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain was observed at 12 months with subsequent improvement at 28 months. The assessment of voiding-symptoms and maximum urinary flow rate (Qmax) showed that no significant difference was measurable at 12 and 28 months. For PVR, a transient increase at 12 months with a subsequent decrease at 28 months was measured. No significant increase in alpha-blockers usage and in the percentage of men with pathological nonintubated uroflowmetry (NIF) was observed at 12 and 28 months. Finally, patients did not perceive any clinical worsening in their quality of life (QoL) as attested by the International Prostate Symptom Score (IPSS)-QoL. Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results. Prostate Cancer and Prostatic Diseases (2010) 13, 34-38; doi:10.1038/pcan.2009.23; published online 23 June 2009

Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer / Tombolini, Vincenzo; M., Di Staso; P., Bonfili; M., Di Genesio Pagliuca; P., Franzese; S., Buonopane; M., Valeriani; MAURIZI ENRICI, Riccardo; C., Festuccia; Gravina, GIOVANNI LUCA. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - STAMPA. - 13:1(2010), pp. 34-38. [10.1038/pcan.2009.23]

Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer

TOMBOLINI, Vincenzo;MAURIZI ENRICI, Riccardo;GRAVINA, GIOVANNI LUCA
2010

Abstract

To value the late genitourinary (GU) morbidity in men treated with a hypofractionated radiotherapy regimen for prostate cancer. Patients with intermediate risk factors according to D'Amico's criteria were selected. The hypofractionated schedule consisted of 15 fractions of 3.63 Gy delivered three times per week for a total dose of 54.3 Gy. Significant changes in storage-symptoms were not found. A significant transient worsening in the score of late effects of normal tissue late effects normal tissue task force (LENT)-subjective, objective, management, analytic (SOMA) urinary-function domain was observed at 12 months with subsequent improvement at 28 months. The assessment of voiding-symptoms and maximum urinary flow rate (Qmax) showed that no significant difference was measurable at 12 and 28 months. For PVR, a transient increase at 12 months with a subsequent decrease at 28 months was measured. No significant increase in alpha-blockers usage and in the percentage of men with pathological nonintubated uroflowmetry (NIF) was observed at 12 and 28 months. Finally, patients did not perceive any clinical worsening in their quality of life (QoL) as attested by the International Prostate Symptom Score (IPSS)-QoL. Our study seems to suggest that our hypofractionated radiotherapy schedule for the treatment of prostate cancer is safe in terms of late urinary morbidity. Further study will be required to confirm our results. Prostate Cancer and Prostatic Diseases (2010) 13, 34-38; doi:10.1038/pcan.2009.23; published online 23 June 2009
2010
hormonal therapy; hypofractionated radiotherapy; ipss; urinary morbidity; uroflowmetry
01 Pubblicazione su rivista::01a Articolo in rivista
Subjective and objective measures of late genitourinary morbidity following hypofractionated radiotherapy in men with prostate cancer / Tombolini, Vincenzo; M., Di Staso; P., Bonfili; M., Di Genesio Pagliuca; P., Franzese; S., Buonopane; M., Valeriani; MAURIZI ENRICI, Riccardo; C., Festuccia; Gravina, GIOVANNI LUCA. - In: PROSTATE CANCER AND PROSTATIC DISEASES. - ISSN 1365-7852. - STAMPA. - 13:1(2010), pp. 34-38. [10.1038/pcan.2009.23]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/399619
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 4
social impact